Table 3.
Demographic data of patients with FSGS according to age of onset.
| N | ≤ 19 y/o | 20–39 y/o | 40–64 y/o | 65–74 y/o | ≥ 75 y/o | P-value |
|---|---|---|---|---|---|---|
| 164 | 164 | 241 | 61 | 25 | ||
| Age of onset (yrs) | 11 (5, 16) | 32 (26, 36) | 51 (44, 59) | 68 (67, 70) | 80 (77, 82) | < 0.001a,b,c,d,e,f,g,h,i |
| Age at renal biopsy (yrs)* | 18 (14, 20) | 34 (28, 38) | 52 (46, 60) | 69 (67, 71) | 82 (78, 83) | < 0.001a,b,c,d,e,f,g,h,i |
| Age of enrollment (yrs) | 24 (20, 33) | 40 (33, 44) | 58 (50, 63) | 70 (67, 76) | 82 (78, 84) | < 0.001a,b,c,d,e,f,g,h,i |
| Male, n (%) | 100 (61.0%) | 86 (52.4%) | 148 (61.4%) | 32 (52.5%) | 12 (48.0%) | 0.233 |
| Present treatment | ||||||
| Oral PSL | 110 (70.1%) | 131 (84.0%) | 197 (83.1%) | 50 (90.9%) | 17 (85.0%) | 0.002a,b,c |
| IV mPSL | 8 (5.1%) | 22 (14.1%) | 21 (8.9%) | 13 (23.6%) | 3 (15.0%) | 0.001a,c,h |
| Cyclosporine | 82 (52.2%) | 77 (49.4%) | 128 (54.0%) | 24 (43.6%) | 11 (55.0%) | 0.395 |
| Mizoribine | 27 (17.2%) | 23 (14.7%) | 21 (8.9%) | 6 (10.9%) | 2 (10.0%) | 0.142 |
| MMF | 21 (13.4%) | 2 (1.3%) | 6 (2.5%) | 0 (0.0%) | 0 (0.0%) | < 0.001a,b,c,d |
| Rituximab | 17 (10.8%) | 12 (7.7%) | 9 (3.8%) | 0 (0.0%) | 0 (0.0%) | 0.007c |
| PSL + cyclosporine | 70 (44.6%) | 69 (44.2%) | 111 (46.8%) | 24 (43.6%) | 10 (50.0%) | 0.458 |
| Dosage of treatment | ||||||
| Oral PSL (mg/day) | 18.0 ± 17.1 | 21.8 ± 16.1 | 17.2 ± 16.4 | 26.9 ± 16.8 | 28.1 ± 19.0 | < 0.001d,e,h,i |
| IV mPSL (mg/day) | 555.6 ± 300.5 | 609.6 ± 237.5 | 508.8 ± 210.2 | 541.7 ± 144.3 | 500.0 ± 0.0 | 0.554 |
| Cyclosporine (mg/day) | 98.9 ± 45.6 | 101.2 ± 39.9 | 91.5 ± 41.3 | 92.1 ± 38.3 | 92.3 ± 54.4 | 0.357 |
| Mizoribine (mg/day) | 145.4 ± 71.4 | 152.2 ± 53.3 | 156.7 ± 87.7 | 141.7 ± 20.4 | 75.0 ± 35.4 | 0.236 |
| MMF (mg/day) | 1631.0 ± 491.3 | 500.5 ± 706.4 | 1166.7 ± 516.4 | – | – | 0.025 |
| Rituximab (mg/month) | 824.4 ± 628.3 | 772.7 ± 606.8 | 833.3 ± 661.4 | – | – | 0.956 |
| Steroid‑resistant NS | 44 (28.0%) | 55 (35.3%) | 81 (34.2%) | 30 (54.5%) | 15 (75.0%) | < 0.001c,d,g,h,i |
| SDNS or FRNS | 82 (52.2%) | 67 (42.9%) | 95 (40.1%) | 16 (29.1%) | 0 (0.0%) | < 0.001c,d,g,i |
| Persistent UP ≥ 0.5 g/gCr | 60 (38.2%) | 86 (55.1%) | 110 (46.4%) | 38 (69.1%) | 17 (85.0%) | < 0.001a,c,d,h,i |
Data are expressed as median (interquartile range), mean ± SD or number (percentage).
FSGS focal segmental glomerulosclerosis, PSL prednisolone, mPSL methylprednisolone, MMF Mycophenolate mofetil, NS nephrotic syndrome, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome.
aP < 0.05, ≤ 19 y/o vs. 20–39 y/o, bP < 0.05, ≤ 19 y/o vs. 40–64 y/o, cP < 0.05, ≤ 19 y/o vs. 65–74 y/o, dP < 0.05, ≤ 19 y/o vs. ≥ 75 y/o, eP < 0.05, 20–39 y/o vs. 40–64 y/o, fP < 0.05, 20–39 y/o vs. 65–74 y/o, gP < 0.05, 20–39 y/o vs. ≥ 75 y/o, hP < 0.05, 40–64 y/o vs. 65–74 y/o, iP < 0.05, 40–64 y/o vs. ≥ 75 y/o. Kruskal–Wallis tests with Bonferroni-corrected P-values.
*Number of missing values, n = 7 (4.3%) in ≤ 19 y/o; n = 7 (4.3%) in 20–39 y/o; n = 7 (2.9%) in 40–64 y/o; n = 2 (3.3%) in 65–74 y/o; n = 0 (0.0%) in ≥ 75 y/o.